Literature DB >> 17724700

UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease.

Deepika S Darbari1, Ron H N van Schaik, Edmund V Capparelli, Sohail Rana, Robert McCarter, John van den Anker.   

Abstract

The purpose of the study was to determine if UDP-glucuronosyltransferase (UGT) 2B7 allelic variants encoding for UGT2B7, primary enzyme responsible for morphine glucuronidation contribute to the variability in the hepatic clearance of morphine in sickle cell disease (SCD). Twenty-four hour PK study of morphine and UGT2B7 variants genotyping was performed in 20 SCD patients in a steady state of health. Presence of the -840G allele (GG and GA) was associated with lower morphine metabolites/morphine AUC ratio compared with AA genotype (1.8 +/- 0.5 vs. 3.0 +/- 1.8 for M6G/M and 10.1 +/- 2.7 vs. 15.7 +/- 9.4 for M3G/M) (P = 0.03). Presence of UGT2B7 -840G allele is associated with significantly reduced glucuronidation of morphine and thus contributes to the variability in hepatic clearance of morphine in SCD. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17724700     DOI: 10.1002/ajh.21051

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  17 in total

1.  Increased clearance of morphine in sickle cell disease: implications for pain management.

Authors:  Deepika S Darbari; Michael Neely; John van den Anker; Sohail Rana
Journal:  J Pain       Date:  2011-02-01       Impact factor: 5.820

2.  Effects of human SULT1A3/SULT1A4 genetic polymorphisms on the sulfation of acetaminophen and opioid drugs by the cytosolic sulfotransferase SULT1A3.

Authors:  Ahsan F Bairam; Mohammed I Rasool; Fatemah A Alherz; Maryam S Abunnaja; Amal A El Daibani; Katsuhisa Kurogi; Ming-Cheh Liu
Journal:  Arch Biochem Biophys       Date:  2018-04-26       Impact factor: 4.013

Review 3.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

4.  [Interaction of opioid analgesics at the level of biotransformation].

Authors:  H Petri; D Grandt
Journal:  Schmerz       Date:  2016-12       Impact factor: 1.107

5.  Clinical and genetic factors are associated with pain and hospitalisation rates in sickle cell anaemia in Cameroon.

Authors:  Ambroise Wonkam; Khuthala Mnika; Valentina J Ngo Bitoungui; Bernard Chetcha Chemegni; Emile R Chimusa; Collet Dandara; Andre P Kengne
Journal:  Br J Haematol       Date:  2017-12-03       Impact factor: 6.998

6.  Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease.

Authors:  Marianne M Yee; Cassandra Josephson; Charles E Hill; Rosiland Harrington; Marta-Inés Castillejo; Ruan Ramjit; Ifeyinwa Osunkwo
Journal:  J Pediatr Hematol Oncol       Date:  2013-10       Impact factor: 1.289

7.  Prediction of deleterious non-synonymous single-nucleotide polymorphisms of human uridine diphosphate glucuronosyltransferase genes.

Authors:  Yuan Ming Di; Eli Chan; Ming Qian Wei; Jun-Ping Liu; Shu-Feng Zhou
Journal:  AAPS J       Date:  2009-07-02       Impact factor: 4.009

8.  Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.

Authors:  Federico Innocenti; Wanqing Liu; Donna Fackenthal; Jacqueline Ramírez; Peixian Chen; Xin Ye; Xiaolin Wu; Wei Zhang; Snezana Mirkov; Soma Das; Edwin Cook; Mark J Ratain
Journal:  Pharmacogenet Genomics       Date:  2008-08       Impact factor: 2.089

Review 9.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

10.  Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.

Authors:  Renee M Balliet; Gang Chen; Carla J Gallagher; Ryan W Dellinger; Dongxiao Sun; Philip Lazarus
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.